On October 24, 2016, a delegation led by Mr. Sixto, President of BioCollection Worldwide (BCW) of the United States, visited Xiamen Tongren for negotiation.
BCW is one of the most professional research, development and production units of infectious disease diagnostic quality control serum in the United States. Its infectious disease quality control serum covers all genotypes of conventional infectious diseases and new severe infectious diseases. The company owns and controls dozens of sample collection centers in 19 countries including North America, Latin America, Europe and Africa. From the beginning of 2016 to October 2016, more than 110000 samples were collected. BCW has passed the FDA and COLA certification of the United States, mainly serving customers such as Roche, Siemens, Johnson&Johnson, Abbott, etc.
This is Mr. Sixto's first trip to China, which is the beginning of BCW's entry into China. The general manager of Xiamen Tongrenxin and Sixto had an in-depth exchange on the introduction of products to the domestic and domestic quality control serum market. In addition, accompanied by the General Manager of Tongrenxin, we conducted research on Xiamen Vantage Carey, Xiamen Yingke Xinchuang and other customer units.